Parent Project Muscular Dystrophy Awards $750,000 Grant to Sildenafil/Taladafil Study
HACKENSACK, N.J., April 4, 2011 /PRNewswire-USNewswire/ -- Parent Project Muscular Dystrophy (PPMD)  – the largest, most comprehensive non-profit organization in the United States focused on finding a cure for Duchenne muscular dystrophy (Duchenne)  – announced today that they will award Ronald G. Victor, M.D. of Cedars-Sinai Medical Center, a $750,000 grant to fund his study of phosphodiesterase inhibitors (sildenafil and taladafil) as a possible therapy for Duchenne.
Dr. Victor and his team at the Cedars-Sinai Heart Institute in Los Angeles discovered a defect in muscle blood flow in mdx mice  and boys with Duchenne. Correcting this defect with phosphodiesterase inhibitors (sildenafil and taladafil) improves muscle and heart function in mdx mice. Dr. Victor will conduct a clinical research study to determine if these drugs can improve muscle blood flow in boys with Duchenne, with plans to continue on to a larger multi-center clinical outcomes trial examining both heart and muscle function.
PPMD President and CEO Pat Furlong  said that the organization is pleased to support the work of Dr. Victor and Cedars-Sinai. "Parent Project Muscular Dystrophy launched a cardiac initiative at the beginning of this year so that potential treatments in Duchenne took into consideration the effect therapies may have on the heart. Dr. Victor and the wonderful people at Cedars-Sinai have not only taken into consideration cardiac issues in Duchenne, but are also combi